Cargando…
Theoretical design of a new chimeric protein for the treatment of breast cancer
p28 and NRC peptides are two anticancer peptides with various mechanisms have shown to be effective against breast cancer. Therefore, it seems that construction of a chimeric protein containing the two peptides might cause synergistic cytotoxic effects. However, since the two peptides bear opposite...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962299/ https://www.ncbi.nlm.nih.gov/pubmed/27499788 |
_version_ | 1782444808324775936 |
---|---|
author | Soleimani, Meysam Mahnam, Karim Mirmohammad-Sadeghi, Hamid Sadeghi-Aliabadi, Hojjat Jahanian-Najafabadi, Ali |
author_facet | Soleimani, Meysam Mahnam, Karim Mirmohammad-Sadeghi, Hamid Sadeghi-Aliabadi, Hojjat Jahanian-Najafabadi, Ali |
author_sort | Soleimani, Meysam |
collection | PubMed |
description | p28 and NRC peptides are two anticancer peptides with various mechanisms have shown to be effective against breast cancer. Therefore, it seems that construction of a chimeric protein containing the two peptides might cause synergistic cytotoxic effects. However, since the two peptides bear opposite charges, production of a chimeric protein in which the two moieties do not intervene each other is difficult. In this study, our goal was to find a suitable peptide linker for the new chimeric protein in a manner that none of the peptides intervene the other’s function. We selected some linkers with different characteristics and lengths and created a small library of the chimeric proteins harboring these linkers. Homology modeling and molecular dynamic simulation revealed that (PA)(5)P and (EAAAK)(3) linkers can separate the p28 and NRC peptides effectively. Thus, the chimeric protein linked with (PA)(5)P or (EAAAK)(3) linkers might show synergistic and stronger anticancer effects than the separate peptide moieties because they could exert their cytotoxic effects freely which is not influenced by the other part. |
format | Online Article Text |
id | pubmed-4962299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49622992016-08-05 Theoretical design of a new chimeric protein for the treatment of breast cancer Soleimani, Meysam Mahnam, Karim Mirmohammad-Sadeghi, Hamid Sadeghi-Aliabadi, Hojjat Jahanian-Najafabadi, Ali Res Pharm Sci Original Article p28 and NRC peptides are two anticancer peptides with various mechanisms have shown to be effective against breast cancer. Therefore, it seems that construction of a chimeric protein containing the two peptides might cause synergistic cytotoxic effects. However, since the two peptides bear opposite charges, production of a chimeric protein in which the two moieties do not intervene each other is difficult. In this study, our goal was to find a suitable peptide linker for the new chimeric protein in a manner that none of the peptides intervene the other’s function. We selected some linkers with different characteristics and lengths and created a small library of the chimeric proteins harboring these linkers. Homology modeling and molecular dynamic simulation revealed that (PA)(5)P and (EAAAK)(3) linkers can separate the p28 and NRC peptides effectively. Thus, the chimeric protein linked with (PA)(5)P or (EAAAK)(3) linkers might show synergistic and stronger anticancer effects than the separate peptide moieties because they could exert their cytotoxic effects freely which is not influenced by the other part. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4962299/ /pubmed/27499788 Text en Copyright: © Research in Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Soleimani, Meysam Mahnam, Karim Mirmohammad-Sadeghi, Hamid Sadeghi-Aliabadi, Hojjat Jahanian-Najafabadi, Ali Theoretical design of a new chimeric protein for the treatment of breast cancer |
title | Theoretical design of a new chimeric protein for the treatment of breast cancer |
title_full | Theoretical design of a new chimeric protein for the treatment of breast cancer |
title_fullStr | Theoretical design of a new chimeric protein for the treatment of breast cancer |
title_full_unstemmed | Theoretical design of a new chimeric protein for the treatment of breast cancer |
title_short | Theoretical design of a new chimeric protein for the treatment of breast cancer |
title_sort | theoretical design of a new chimeric protein for the treatment of breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962299/ https://www.ncbi.nlm.nih.gov/pubmed/27499788 |
work_keys_str_mv | AT soleimanimeysam theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer AT mahnamkarim theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer AT mirmohammadsadeghihamid theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer AT sadeghialiabadihojjat theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer AT jahaniannajafabadiali theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer |